Arcturus Therapeutics Holdings (ARCT) Profit After Tax (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly Profit After Tax came in at -$27.0 million in Q1 2026, down 91.56% YoY from -$319.5 million in Q1 2025, and up 7.27% on a QoQ basis from -$29.1 million in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) Profit After Tax (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of Profit After Tax data on file, last reported at -$27.0 million in Q1 2026.
- Quarterly Profit After Tax fell 91.56% year-over-year to -$27.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$78.7 million (down 15.35% YoY) and the FY2025 annual result came in at -$65.8 million, up 18.73% from the prior year.
- Profit After Tax rose to -$27.0 million in Q1 2026, from -$29.1 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $117.3 million in Q4 2022 to a low of -$52.6 million in Q2 2023.
- A 5-year average of -$11.4 million and a median of -$17.2 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax soared 403.51% — and 2024, when it tumbled 156.3%.
- Tracing ARCT's Profit After Tax over 5 years: stood at $117.3 million in 2022, then tumbled by 109.98% to -$11.7 million in 2023, then sank by 156.3% to -$30.0 million in 2024, then rose by 3.09% to -$29.1 million in 2025, then gained by 7.27% to -$27.0 million in 2026.
- The last three Profit After Tax figures came in at -$27.0 million (Q1 2026), -$29.1 million (Q4 2025), and -$13.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Arcturus Therapeutics Holdings | 233.92 Mn | 42.44 Mn | - | -23.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.79 Mn |
| Mar 31, 2026 | -26.96 Mn |
| Dec 31, 2025 | -29.08 Mn |
| Sep 30, 2025 | -13.45 Mn |
| Jun 30, 2025 | -9.18 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -30.01 Mn |
| Sep 30, 2024 | -6.90 Mn |
| Jun 30, 2024 | -17.22 Mn |
| Mar 31, 2024 | -26.82 Mn |
| Dec 31, 2023 | -11.71 Mn |
| Sep 30, 2023 | -16.22 Mn |
| Jun 30, 2023 | -52.55 Mn |
| Mar 31, 2023 | 50.75 Mn |
| Dec 31, 2022 | 117.35 Mn |
| Sep 30, 2022 | -35.27 Mn |
| Jun 30, 2022 | -21.56 Mn |
| Mar 31, 2022 | -51.17 Mn |
| Dec 31, 2021 | -38.66 Mn |
| Sep 30, 2021 | -54.08 Mn |